The next major innovation in Type 2 diabetes may not come from another drug. It could come through an endoscope.
In this episode, Omar M. Khateeb , CEO of MarketCraft, sits down with Bob Haggerty, President and CEO of Aqua Medical , to explore an emerging MedTech category known as Endoscopic Metabolic Restoration and what it could mean for the future of metabolic care.
Aqua Medical is developing an investigational procedure designed to treat the proximal intestinal mucosa using radiofrequency-generated water vapor delivered through a standard endoscope.
The premise is compelling because the proximal small intestine plays an important role in nutrient sensing and glycemic regulation. In patients with Type 2 diabetes, that tissue can become dysfunctional, creating an opportunity to investigate whether treating the area could influence metabolic control.
Several themes from the conversation stand out:
- Early clinical data is creating an important signal. Bob discusses Aqua Medical’s 66-patient international experience, where average A1C reductions of approximately 2.1 to 2.6 points were observed at one year.
- The future may be procedure plus pharmaceutical, not procedure versus pharmaceutical. Bob sees potential for endoscopic therapy to complement GLP-1s, oral medications, insulin, diet, and lifestyle changes depending on the patient.
- Workflow can be as important as technology. Aqua designed its device to pass through the working channel of existing endoscopes and fit into procedures gastroenterologists already perform in ambulatory surgery centers.
- Healthcare economics matter. Diabetes creates years of recurring medication, monitoring, and complication-related costs. Determining whether a procedural intervention can reduce part of that long-term burden will require additional clinical and economic evidence.
- Commercialization starts long before launch. Aqua Medical is using its recent Series B financing to advance its U.S. clinical program and prepare for a planned pivotal trial as the company works toward the evidence required for potential future commercialization.
The broader implication extends beyond Aqua Medical.
MedTech is increasingly moving from devices that diagnose or support chronic disease toward interventions that may directly modify the treatment pathway.
If metabolic endoscopy continues to generate compelling evidence, gastroenterologists could eventually play a very different role in the management of diseases traditionally dominated by endocrinology and pharmaceuticals.
That is what makes this category worth watching.